| Explore this extended half-life therapy.
|
|
|
|
|
|
Esperoct®
is used to treat and prevent or reduce the
number of bleeding episodes in people with
hemophilia A.
|
|
|
|
|
Elevate your factor levels and reduce severity
|
|
|
If you are an adult or adolescent with severe hemophilia A,
treating with Esperoct®
50 IU/kg every 4 days could help you
achieve factor levels defined as mild for 90% of the
time and mild-to-moderate for 100% of the time.a,b
|
|
|
|
|
|
a
|
Mild hemophilia A was defined as factor VIII (FVIII)
activity >5 IU/dL (>5% of normal), moderate as 1-5 IU/dL
(1-5% of normal), and severe as <1 IU/dL (<1% of
normal).
|
|
b
|
Steady-state factor VIII (FVIII) activity levels were
estimated in 143 adults and adolescents using PK modeling.
|
|
|
Scroll and learn how Esperoct®
impacts children.
|
|
|
|
Selected Important Safety Information
|
|
Who should not use Esperoct®?
|
| |
•
|
You should not use Esperoct®
if you are allergic to factor VIII or any of the
other ingredients of Esperoct®
or if you are allergic to hamster proteins
|
|
|
What is the most important information I need to know about
Esperoct®?
|
| |
•
|
Do not attempt to do an infusion yourself
unless you have been taught how by your
healthcare provider or hemophilia treatment
center
|
|
| |
•
|
Call your healthcare provider right away or
get emergency treatment right away if you
get any signs of an allergic reaction, such
as:
hives, chest tightness, wheezing, dizziness,
difficulty breathing, and/or swelling of the
face
|
|
|
Please
click here
or scroll below for additional Important Safety Information.
|
|
|
|
From severe to mild: Esperoct®
helps children too.
|
|
|
With Esperoct®
60 IU/kg (50-75 IU/kg) twice weekly, children <12 years
with severe hemophilia A could
achieve factor levels defined as mild for 72% of the
time and mild-to-moderate for 97.9% of the time.a,c
|
|
|
|
c
|
Steady-state factor VIII (FVIII) activity levels
were estimated using PK modeling in children
<12 years. Twice weekly dosing was a dosing
interval of every 3 or 4 days.
|
|
|
|
|
What is Esperoct®?
|
|
Esperoct®
[antihemophilic factor (recombinant), glycopegylated-exei]
is an injectable medicine to treat and prevent or reduce the
number of bleeding episodes in people with hemophilia A.
Your healthcare provider may give you Esperoct®
when you have surgery
|
| |
•
|
Esperoct®
is not used to treat von Willebrand Disease
|
|
|
Important Safety Information (cont’d)
|
|
What should I tell my healthcare provider before using
Esperoct®?
|
| |
•
|
Before taking Esperoct®, you should tell your healthcare provider if
you have or have had any medical conditions,
take any medicines (including non-prescription
medicines and dietary supplements), are nursing,
pregnant or planning to become pregnant, or have
been told that you have inhibitors to factor
VIII
|
| |
•
|
our body can make antibodies called “inhibitors”
against Esperoct®, which may stop Esperoct®
from working properly.
Call your healthcare provider right away if
your bleeding does not stop after taking
Esperoct®
|
|
|
What are the possible side effects of Esperoct®?
|
| |
•
|
Common side effects of Esperoct®
include rash or itching, and swelling, pain,
rash or redness at the location of infusion
|
|
|
Please
click here
for Prescribing Information.
|
|
Esperoct®
is a prescription medication.
|
|
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.
|
|
|
|
|
Esperoct®
is a registered trademark of Novo Nordisk Health Care
AG.
Novo Nordisk is a registered trademark of Novo
Nordisk A/S.
© 2020 Novo
Nordisk All rights reserved.
US20ESP00119
January 2021
|
|
|
|
|